Aeterna Zentaris Inc. (NASDAQ:AEZS)’s share price fell 4.3% on Tuesday . The company traded as low as $3.36 and last traded at $3.37, with a volume of 166,411 shares. The stock had previously closed at $3.52.

A number of brokerages have recently weighed in on AEZS. HC Wainwright reiterated a “buy” rating and set a $12.00 target price on shares of Aeterna Zentaris in a research note on Sunday, July 10th. Maxim Group reiterated a “buy” rating and set a $11.00 target price on shares of Aeterna Zentaris in a research note on Monday, May 2nd. Finally, Canaccord Genuity reiterated a “buy” rating and set a $9.00 target price (down previously from $13.00) on shares of Aeterna Zentaris in a research note on Monday, April 4th.

The company’s market cap is $33.59 million. The company has a 50-day moving average price of $3.45 and a 200-day moving average price of $3.45.

Aeterna Zentaris Inc is a Canada-based specialty biopharmaceutical company engaged in developing treatments in oncology, endocrinology and women’s health. The Company has three wholly owned direct and indirect subsidiaries: AEZS GmbH, based in Frankfurt, Germany, Zentaris IVF GmbH, a direct wholly owned subsidiary of AEZS Germany based in Frankfurt, Germany, and Aeterna Zentaris, Inc Its drug development efforts are focused on two compounds, zoptarelin doxorubicin and Macrilen, which are in clinical development, and on two oncology compounds (an Erk inhibitor and Luteinizing Hormone-Releasing Hormone-disorazol Z product candidates), which are in pre-clinical development.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.